|
HHS Behavioral Health Coordinating Council (BHCC)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA
|
NIDA, OD/IMOD
|
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Behavioral Health Integration Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA
|
NIAAA, NIDA, NIMH
|
The Behavioral Health/Primary Care Integration Subcommittee addresses the need to improve the integration of mental health and primary care services. This group convenes bi-monthly to share agency initiatives in this area and collaborate on new initiatives to promote this integration.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Buprenorphine Availability Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA
|
NIAAA, NICHD, NIDA, NIMH
|
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Children and Youth Behavioral Health Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA, HRSA, OASH, SAMHSA
|
NICHD, NIDA, NIMH
|
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Children and Youth Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, IHS, OASH, OSG, SAMHSA
|
NICHD, NIDA, NIMH, NIMHD
|
Subcommittee of HHS Behavioral Health Coordinating Council (BHCC), addressing these high level priorities: • Ensure children, youth, and caregivers have access to appropriate behavioral health prevention resources, screening, referral, and treatments in their communities, schools, and early education settings.• Address behavioral health needs resulting from the COVID-19 pandemic. • Advance health equity by addressing the health needs of underserved communities. • Support the behavioral health workforce that serves children and youth.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Contingency Management Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA
|
NIAAA, NICHD, NIDA, NIMH
|
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Expanding Access to Naloxone Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA
|
NIAAA, NICHD, NIDA, NIMH
|
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; and determining the public health impact of kratom scheduling; and improving clinician education on controlled substance prescribing.
|
|
HHS Behavioral Health Coordinating Council (BHCC), High Dose Buprenorphine Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; assessing the landscape of prescription stimulant use and misuse; and improving clinician education on controlled substance prescribing.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Overdose Prevention Strategy Primary Prevention Metrics Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; assessing the landscape of prescription stimulant use and misuse; and improving clinician education on controlled substance prescribing.
|
|
HHS Behavioral Health Coordinating Council (BHCC), Overdose Prevention Strategy Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
FDA, AHRQ, ASPE, CDC, CMS, HRSA, IHS, OASH, SAMHSA
|
NIAAA, NICHD, NIDA, NIMH
|
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; assessing the landscape of prescription stimulant use and misuse; and improving clinician education on controlled substance prescribing.
|